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Background
Assessment of tumor-infiltrating immune cells using
immunohistochemistry (IHC) has been shown to be a
powerful way to predict patient prognosis, notably in
colon cancer [1, 2]. Similar observations were made in
patients with head and neck squamous cell carcinoma
(HNSCC), where T cell infiltration is associated with
prolonged survival [3,4]. More recently, efforts in multi-
plex imaging were made to address suppressive mechan-
isms within the tumor microenvironment and how they
impact the overall anti-tumor immune response. We
hypothesize that the implications of such work can
direct immunotherapy treatment strategies.
Purpose
Apply multiplex immunohistochemistry of HNSCC sam-
ples in order to identify immune biomarkers that corre-
late with prognosis and to further explore whether
relationship analysis provides insights into tumor resis-
tance mechanisms.
Methods
30 samples from Providence Cancer Center and 80 sam-
ples from Halle Medical Center are included in this study.
The majority of these samples are HPV negative. Slides
were prepared from formalin fixed paraffin embedded
(FFPE) samples of patients’ primary tumor and stained for
CD3, CD8, FoxP3, CD163, PD-L1, Cytokeratin and DAPI
using the PerkinElmer Opal system. Digital imaging and
analysis were done using PerkinElmer Vectra and inform
software. Conventional IHC was performed for analysis of
the HLA class I antigen processing machinery (APM)
using antibodies directed against HLA class I heavy chain,
b2-microglobulin and the transporter associated with anti-
gen processing subunits TAP1 and TAP2.
Results
Preliminary data from 50 HPV- samples indicated an
extremely heterogeneous expression of HLA class I
APM components in the HNSCC tumor lesions, which
is currently associated with disease progression and
immune cell infiltration. In addition, a CD3+/CD8-/
FoxP3- immune infiltrate at the invasive margin was
highly predictive of survival (p=0.001). Interestingly, a
FoxP3+ infiltrate at the invasive margin was also highly
predictive of survival (p=0.001). Current studies are
evaluating the potential relationships between these two
cell populations, as well as their relationship with the
tumor immune escape phenotype and with other cells
in the tumor environment.
Conclusion
Preliminary conclusions from our small cohort suggest a
strong association between infiltrates of CD3+CD8-cells
and increased survival. Interestingly, expression of
FoxP3 by these cells did not negatively impact patient
prognosis.
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